Cargando…
Higher graft cell dose does not influence development of acute or chronic GVHD in haploidentical transplantation using PTCy
Autores principales: | Nawas, Mariam T., Im, Annie, Shaffer, Brian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440450/ https://www.ncbi.nlm.nih.gov/pubmed/37315168 http://dx.doi.org/10.1182/bloodadvances.2023010369 |
Ejemplares similares
-
PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation
por: Al-Homsi, A. Samer, et al.
Publicado: (2023) -
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT
por: Baron, Frédéric, et al.
Publicado: (2023) -
Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy
por: Zou, Jun, et al.
Publicado: (2022) -
Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression
por: Nakamura, Makoto, et al.
Publicado: (2021) -
PB2439: EARLIER ENGRAFTMENT WITHOUT INCREASE OF GVHD IN HIGHER DOSE OF CD34+ CELLS IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tan, Tran-Der, et al.
Publicado: (2023)